Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Citius Pharmaceuticals ( (CTXR) ) is now available.
On October 23, 2025, Citius Pharmaceuticals announced the upcoming commercialization of LYMPHIR, a treatment for cutaneous T-cell lymphoma, planned for Q4 2025. This follows its FDA approval in August 2024 and is expected to impact the U.S. market significantly, with an estimated addressable market of over $400 million. The company has invested heavily in pre-commercial activities, including securing distribution agreements and developing a marketing strategy, positioning itself strongly in the oncology market.
The most recent analyst rating on (CTXR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.
Spark’s Take on CTXR Stock
According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.
Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.
To see Spark’s full report on CTXR stock, click here.
More about Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies, particularly in the oncology sector. The company has multiple advanced development programs, including LYMPHIR for cutaneous T-cell lymphoma, Mino-Lok for catheter-related bloodstream infections, and Halo-Lido for hemorrhoids.
Average Trading Volume: 719,773
Technical Sentiment Signal: Sell
Current Market Cap: $28.58M
Find detailed analytics on CTXR stock on TipRanks’ Stock Analysis page.